Michael Hill, PhD

Dr. Michael Hill’s research interest is in the neuropharmacology of Parkinson’s disease, with a particular focus on understanding the complex interactions among the various neurotransmitter systems affected by the condition. With over 25 years of experience in the preclinical CRO sector, Michael has dedicated his career to advancing Parkinson’s disease research and driving the development of innovative and more effective treatments. He has played a pivotal role in the development of numerous therapeutics, collaborating extensively with both large pharmaceutical companies and biotech firms to strategically guide their pre-clinical programs toward successful clinical trials.